NCT05438368: GD2/CD70 Bi-specific CAR-T Cell Therapy
- State
- Not started
- Phase
- Phase 1 and Phase 2
- People
- 30 planned
- Started
- 31 Dec 2026
- Primary completion
- 31 Dec 2029
- Arms
- bi-4SCAR-GD2/CD70 T Cell Therapy for GD2 and/or CD70 positive tumor
- Results
- None posted
- 30 Jun 2022: Trial registered